Review of Topiramate: An Antiepileptic for the Treatment of Alcohol Dependence
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Despite the availability of currently approved medications and various psychosocial therapies, alcohol abuse and dependence are increasingly prevalent in the United States, and carry a significant socioeconomic burden. Recently, the novel anti-epileptic topiramate has shown great promise as a new treatment for this disorder. The objective of this review is to discuss the limitations of the currently available options for treating alcohol dependence, to review the results of clinical trials assessing the efficacy of topiramate in treating alcohol dependence, and to describe the pharmacological characteristics and mechanisms of action of topiramate as related to this indication. We systematically reviewed Medline, EMBASE, Cochran Reviews and PsycINFO search terms included combinations of the terms "pharmacotherapy" "topiramate", "alcoholism" and "alcohol dependence." Searches were last updated 24 October 2008. Currently approved treatments include disulfiram, naltrexone tablets and injection, and acamprosate. Of these, naltrexone has shown the most benefit, however the effect size is small and may reach its most promising potential when combined with medical management. Alternatively, through multiple mechanisms of action, topiramate in clinical trials has demonstrated safety and efficacy in decreasing both craving and withdrawal symptoms and increasing quality of life measures among alcohol-dependent individuals. The findings of this review suggest that topiramate is a promising new option for the treatment of alcohol dependence, and may offer substantial benefits over currently approved medications. While the manufacturer will not pursue approval of an indication for the treatment of alcohol dependence, the drug will soon be available generically, making it more affordable for a greater proportion of the public.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bohn, M. J., Babor, T. F., & Kranzler, H. R. (1995) · Journal of Studies on Alcohol · doi:10.15288/jsa.1995.56.423 · Cited by 1,356
Oral topiramate for treatment of alcohol dependence: A randomised controlled trial
Johnson, B. A., Ait-Daoud, N., Bowden, C. L., DiClemente, C. C., Roache, J. D., Lawson, K., Javors, M. A., & Ma, J. Z. (2003) · The Lancet · doi:10.1016/s0140-6736(03)13370-3 · Cited by 743
Psychometric properties of the Medical Outcomes Study Sleep measure
Hays, R. D., Martin, S. A., Sesti, A. M., & Spritzer, K. L. (2005) · Sleep Medicine · doi:10.1016/j.sleep.2004.07.006 · Cited by 557
Topiramate for Treating Alcohol Dependence<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>
Johnson, B. A. (2007) · JAMA · doi:10.1001/jama.298.14.1641 · Cited by 542
Ray, L. A., & Hutchison, K. E. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.9.1069 · Cited by 258 · cited 1×
“genotyping associated with familial risk [12], in which naltrexone may be moderated by variations in the mu-opioid receptor gene (OPRM1) [4, 16 ].”
BackgroundComparing topiramate with naltrexone in the treatment of alcohol dependence
Baltieri, D. A., Daró, F. R., Ribeiro, P. L., & De Andrade, A. G. (2008) · Addiction · doi:10.1111/j.1360-0443.2008.02355.x · Cited by 145
Cited by
Advances in the science and treatment of alcohol use disorder
Witkiewitz, K., Litten, R. Z., & Leggio, L. (2019) · Science Advances · doi:10.1126/sciadv.aax4043 · Cited by 592
Self-citationTreatment options for alcoholic and non-alcoholic fatty liver disease: A review
Singh, S., Osna, N. A., & Kharbanda, K. K. (2017) · World Journal of Gastroenterology · doi:10.3748/wjg.v23.i36.6549 · Cited by 257
Novel Agents for the Pharmacological Treatment of Alcohol Use Disorder
Burnette, E. M., Nieto, S. J., Grodin, E. N., Meredith, L. R., Hurley, B., Miotto, K., Gillis, A. J., & Ray, L. A. (2022) · Drugs · doi:10.1007/s40265-021-01670-3 · Cited by 169
“It is worth noting a potential strength of topiramate: the possibility of starting treatment while patients are still actively drinking, allowing topiramate to serve as a harmreduction or abstinence-initiation treatment, rather than only being used to prevent relapse in already detoxified patients [120].”
BackgroundRezvani, A. H., Slade, S., Wells, C., Petro, A., Lumeng, L., Li, T.-K., Xiao, Y., Brown, M. L., Paige, M. A., McDowell, B. E., et al. (2010) · Psychopharmacology · doi:10.1007/s00213-010-1878-8 · Cited by 88
“Alcoholism is a complex heterogeneous disease and consequently existing pharmacological tools such as disulfiram (Antabuse®), naltrexone (ReVia®), and acamprosate (Campral®), while efficacious in some (O'Malley et al. 1992; Kenna et al. 2009; Mann et al. 2008), leave many others unaided (Garbutt 2009; Kranzler and van…”
Nourredine, M., Jurek, L., Angerville, B., Longuet, Y., de Ternay, J., Derveaux, A., & Rolland, B. (2021) · CNS Drugs · doi:10.1007/s40263-020-00780-y · Cited by 26
“Topiramate inhibits fructose-1,6-bisphosphatase, making it a potential gluconeogenesis inhibitor [1, 2].”
Background
Metadata
- Authors
- Kenna, G., Lomastro, T., Schiesl, A., Leggio, L., & Swift, R.
- Venue
- Current Drug Abuse Reviewse
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2009-05-01
- Volume
- 2
- Issue
- 2
- Pages
- 135-142
- ISSN
- 1874-4737 (ISSN-L)
- OpenAlex
- W2133231508
- Cited by
- 73
- References
- 6
- FWCI
- 4.73
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Review of Topiramate: An Antiepileptic for the Treatment of Alcohol Dependence. https://app.cochat.ai/papers/10.2174/1874473710902020135
- The paper
- Kenna, G., Lomastro, T., Schiesl, A., Leggio, L., & Swift, R. (2009). Review of Topiramate: An Antiepileptic for the Treatment of Alcohol Dependence. Current Drug Abuse Reviewse. https://doi.org/10.2174/1874473710902020135
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.